Viz.ai

Clinical AI company whose platform analyses CT and other imaging for suspected stroke and other time-critical findings and notifies the treating team on a mobile app.

viz.ai

At a glance

Headquarters: San Francisco, United States
Founded: 2016
Business model: B2B
Products profiled: 1
Operating markets: United States
Sources cited: 3
In the library since: 24 September 2026

What it does

Viz.ai's software analyses CT and other imaging for suspected stroke, haemorrhage, aneurysm, pulmonary embolism and cardiac findings, and notifies the treating team through a mobile app to coordinate care.

Independent evidence

Established from a source other than the company.

FDA records for the applicant Viz. Ai, Inc. run from K180161 (2018) to K250354 (10 June 2025), under product codes including QAS (radiological computer-assisted triage and notification software), QIH, QFM and LLZ, with the De Novo DEN230003 (Viz HCM, 2023). A total clearance count is not given here because the company's figure has not been reconciled with the FDA's records.

What the company says

The company’s own statements, attributed to it and not presented as established fact.

The company says the Viz Platform is deployed in 2,000 hospitals in the United States and has reached 230 million patients. It marked ten years in July 2026, which dates its founding to 2016.

Press datelines and most FDA records give San Francisco; the most recent FDA record (K250354) lists Cary as the applicant city. The funding stage is not recorded because the latest round was not verified.